Últimas noticias sobre Petros Pharma (NASDAQ:PTPI) Bolsa

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

News

Laboratory Corporation Of America Holdings

NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025

VS: 489% &#x7C; <a href="https://www.benzinga.com//node/41354474">Versus Systems shares are trading higher after the company announced a $2.5 million investment and licensing agreement with ASPIS.</a>
&nbsp;
NVAX: -32% &#x7C; <a href="https://www.benzinga.com//node/41355032">Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</a>
&nbsp;
BDRX: 245% &#x7C; <a href="https://www.benzinga.com//node/41354484">Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.</a>

Movers

Trading Ideas

BDRX

NVAX

Market-Moving News for October 16th

Roth MKM analyst Scott Stember reinstates AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and announces $3634 price target.

Price Target

Initiation

Analyst Ratings

Roth MKM Reinstates Buy on AutoZone, Announces $3634 Price Target

Alaska Airlines Enhances Mileage Plan For 2025 With New Perks, Faster Elite Status Earning, And Expanded Options For Earning And Redeeming Miles; Single Loyalty Program Coming As Alaska And Hawaiian Airlines Merge

WIIM

ULTA

Ulta Beauty shares are trading lower after the company provided long-term business strategy plans and reaffirmed its F24 guidance.

A high-stakes power struggle has erupted between Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and activist investor Starboard Value, with Wall Street&#8217;s dealmaker, Alan Schwartz, and his firm, Guggenheim Partners, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41199793/amid-pfizers-struggles-with-declining-demand-for-covid-19-treatments-activist-investor-starboard" rel="noreferrer noopener">caught in the crossfire</a>.
The activist investor had built a $1 billion&nbsp;stake&nbsp;in the U.S. drug maker. The tension peaked when Pfizer&#8217;s former CEO Ian Read and former CFO Frank D&#8217;Amelio, who initially supported Starboard&#8217;s campaign against Pfizer&#8217;s current CEO Albert Bourla, unexpectedly <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" rel="noreferrer noopener">reversed their stance</a>.
Read and D&#8217;Amelio issued a statement expressing full support for Bourla and the board, though this sudden shift in allegiance left insiders puzzled.
Even more surprising was that the statement was released through Guggenheim, a firm that has enjoyed a close relationship with Pfizer and has earned approximately $172 million in advisory fees since 2011, most recently $48 million from the&nbsp;Seagen deal.
Speculation surrounds the reversal, with Jeff Smith, CEO of Starboard, claiming Pfizer pressured the ex-executives with potential legal consequences <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41274121/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">and bonus clawbacks</a>.
Despite not playing an official role in the Starboard-Pfizer dispute, Guggenheim finds itself entangled in one of Wall Street&#8217;s most contentious activist campaigns.
The Financial Times <a target="_blank" href="https://www.ft.com/content/1546d1e6-3bd6-43d8-b17a-919308096ef0" rel="noreferrer noopener">notes</a> that Pfizer has since turned to rival boutique firm PJT Partners to lead its defense, distancing itself from its long-time advisor in this high-profile clash.
Starboard&#8217;s frustration stems from Pfizer&#8217;s declining performance since its COVID-19 vaccine windfall. The company has faced criticism for a series of costly acquisitions, including its $43 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">purchase of </a><a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">Seagen</a>.
The FT report highlights that Starboard <a target="_blank" href="https://www.ft.com/content/0f3e13bd-ba02-47a6-9261-1e49d19d6528" rel="noreferrer noopener">argues</a> that these moves, along with poor capital allocation, have contributed to Pfizer&#8217;s stock dropping over 50% from its pandemic peak. The activist investor will likely push for significant changes, possibly including a leadership overhaul or further divestitures.
With Pfizer&#8217;s stagnant revenue growth and limited options for quick fixes, Starboard&#8217;s path to reshaping the company remains uncertain.
Pfizer has already implemented cost-cutting measures and sold off divisions, leaving few levers for change.
Price Action: PFE stock is up 0.31% at $29.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" target="_blank" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug Within Six Months</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle

Roth MKM analyst Scott Stember reinstates O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and announces $1337 price target.

ORLY

Roth MKM Reinstates Buy on O'Reilly Automotive, Announces $1337 Price Target

TD Cowen analyst Krish Sankar maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $23 to $20.

SVCO

TD Cowen Maintains Buy on Silvaco Group, Lowers Price Target to $20

U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The company reported <a target="_blank" href="https://s203.q4cdn.com/711684571/files/doc_financials/2024/q3/Press-Release-3Q24.pdf" rel="noreferrer noopener">third-quarter</a> adjusted earnings per share of $1.03, beating the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41353142/u-s-bancorp-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus estimate of 99 cents.</a>
Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
The third quarter included $119 million of net losses on investment securities sales ($89 million net-of-tax), which was largely offset by lower income tax expenses, which reflected certain tax settlements.
&#8220;Our expense levels decreased year-over-year which supported modest positive operating leverage, excluding net securities losses and prior year notable items,&#8221; said Andy Cecere, Chairman and CEO, U.S. Bancorp.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" rel="noreferrer noopener">Banks Gear Up For Earnings Season: 15 Top Stock Picks Including Citigroup, Morgan Stanley, And Truist</a>
Net interest income fell 2.4% to $4.135 billion in the quarter under review, due to the impact of higher interest rates on deposit mix and pricing. Third quarter noninterest income of $2.698 billion, down 2.4% year over year.
The provision for credit losses increased by $42 million (8.2%) compared with the third quarter of 2023, largely due to higher losses on credit card, commercial, and commercial real estate loans.
&#8220;Credit quality results were in line with expectations, and we continue to increase our capital position, ending the quarter with a CET1 capital ratio of 10.5%,&#8221; Cecere added. The CET1 capital ratio of 10.5% on September 30 was up from 10.3% on June 30.
The average total deposits for the third quarter were $3.5 billion, which was 0.7% lower year over year.
Price Action: USB shares are trading higher by 1.91% to $47.90 premarket at last check Wednesday.
Photo by JHVEPhoto via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41249837/s-p-500-earnings-season-kicks-off-why-analysts-call-this-quarter-a-stock-pickers-paradise" target="_blank" rel="noreferrer noopener">S&amp;P 500 Earnings Season Kicks Off: Why Analysts Call This Quarter ‘A Stock Picker's Paradise'</a></li>
</ul>

Earnings

Equities

Guidance

Markets

U.S. Bancorp Q3 Earnings: EPS Beat, Revenue Miss, Rising Credit Loss Provisions & More

<a href="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture" title="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture">https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture</a>

'BlackRock in Talks With Ambani for India Private Credit Venture' - Bloomberg

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) are surging, with the former benefitting from social media chatter about Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41220500/elon-musk-says-potential-doge-department-under-a-trump-administration-will-be-a-garbage-co">heading a &#8220;D.O.G.E&#8221; department. </a>
What Happened: Dogecoin, Shiba Inu and Dogecoin-themed cryptocurrencies have performed exceptionally well over the past 24 hours:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Market cap</td>
<td>  24-hour trend</td>
<td>7-day trend</td>
</tr>
<tr>
<td>Dogecoin </td>
<td>$0.1256</td>
<td>$18.386B</td>
<td> +11.2%</td>
<td>+15.1%</td>
</tr>
<tr>
<td>Shiba Inu </td>
<td>$0.00001875</td>
<td>$11.04B</td>
<td> +5.2%</td>
<td>+7.2%</td>
</tr>
<tr>
<td>Department Of Government Efficiency (D.O.G.E)</td>
<td>$0.026</td>
<td>$25.68M</td>
<td>+122.4%</td>
<td>+152.4%</td>
</tr>
</tbody>
</table>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313977/dogecoins-on-chain-data-chart-patterns-flash-bullish-signals-this-top-analyst-thinks-its-a">Dogecoin&#8217;s On-Chain Data, Chart Patterns Flash Bullish Signals: This Top Analyst Thinks It&#8217;s A &#8216;Buy&#8217;</a>
Trader Notes: Crypto analysts are speculating on the potential impact of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313912/harris-or-trump-bitcoin-to-be-in-win-win-position-irrespective-of-who-wins-the-white-house">a Trump victory</a> in the upcoming U.S. presidential election on certain cryptocurrencies, particularly those associated with the &#8220;DOGE&#8221; narrative.
Andrew Kang <a href="https://x.com/Rewkang/status/1846231275847454786">suggests</a> that owning Dogecoin and other meme coins could be &#8220;one of the most interesting ways to express a &#8216;Trump Victory&#8217; trade.&#8221; He points to the increased likelihood of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39334602/arthur-hayes-raoul-pal-predict-dogecoin-etf-if-people-wait-in-line-for-luxury-brands-they-">Dogecoin ETF</a> and the potential creation of a<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40780511/dogecoin-surges-8-as-elon-musk-jokes-doge-will-be-the-official-mascot-of-department-of-gov"> Department of Government Efficiency (DOGE)</a> under a Trump administration, which could keep the cryptocurrency in the headlines.
Supporting this view, analyst Unipcs <a href="https://x.com/theunipcs/status/1846474366684438605">highlights</a> the recent performance of DOGE-related assets, stating, &#8220;it&#8217;s hard not to be bullish on both doges if you really think Trump is going to win.&#8221; 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Statistics: IntoTheBlock data shows Dogecoin's large transaction volume increasing by 4.6% and daily active addresses falling by 1.5%. Transactions greater than $100,000 are up from&nbsp; 317 to 394 in a single day.
Shiba Inu's large transaction volume is down by 24.5% and daily active addresses are up by 17.2%. Shiba Inu has burned around 3 million SHIB coins from its ecosystem over the past 24 hours.
Community News: The official Dogecoin account picked up on a Shiba Inu-themed easter egg in Tesla&#8217;s Robotaxi presentation:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hey <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> is that a Shiba Inur taxi? <a href="https://t.co/ihfktgc4ds">pic.twitter.com/ihfktgc4ds</a>
&mdash; Dogecoin (@dogecoin) <a href="https://twitter.com/dogecoin/status/1844591727656448375?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin-themed account Doge Designer <a href="https://x.com/cb_doge/status/1844595234316943841">noted</a> the same, wondering whether Musk would really allow purchases with Dogecoin in the future.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41312634/dogecoin-killer-shiba-inu-incinerates-277m-coins-in-1-transaction-watch-these-levels-for-a">&#8216;Dogecoin Killer&#8217; Shiba Inu Incinerates 277M Coins In 1 Transaction: Watch These Levels For A Bullish Rally</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Dogecoin Rockets Up 10%, Shiba Inu Spikes 5%: What Is Going On?

The soaring price of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stock over the last year has added to the wealth of CEO and co-founder Jensen Huang, making him one of th<a href="https://www.benzinga.com/news/management/24/10/41302431/elon-musk-to-end-year-as-richest-man-in-the-world-prediction-market-says-yes-higher-chance-than-l">e world's richest people.</a>
While Huang is humble about his growing wealth, here's a look at how close the Nvidia CEO is to cracking the top 10 list.
What Happened: In a recent interview, Huang said he <a href="https://www.benzinga.com/news/management/24/10/41294313/does-jensen-huang-check-nvidia-stock-price-daily">doesn't look at the daily price</a> of Nvidia stock and the price doesn't impact how good or bad he feels.
"Not every day, sometimes I'll look at the end of the day," Huang recently said.
Since he doesn't look at the stock price every day, Huang also probably doesn't keep an eye on the Bloomberg Billionaire's Index, which <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">ranks </a>the richest people in the world.
Huang has rapidly risen up the ranks, growing his wealth from $32 billion at the beginning of 2023 to $121 billion, now holding the 11th spot on the list.
While catching up to Elon Musk ($241 billion) might take years—or a significant decline in Tesla and SpaceX's value—Huang could break into the top 10 soon.
Huang trails Google co-founder Sergey Brin, who ranks 10th at $141 billion, by $20 billion.
Owning about 3.5% of Nvidia, which is his primary source of wealth, Huang would need Nvidia to gain $571.4 billion in market capitalization to surpass Brin.
Adding that much to the market capitalization would make Nvidia the most valuable company in the world once again with a value of $3.788 trillion, ranking ahead of Apple's $3.550 trillion.
This, of course, assumes Apple and Brin's wealth will stay the same in value.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
 Why It's Important: While adding $571 billion to a market capitalization would be no small feat, Nvidia has shown impressive valuation metrics in recent years.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club" target="_blank" rel="noreferrer noopener">became a $1 trillion company</a>&nbsp;in May 2023 based on market capitalization, joining a limited number of public companies to hit the milestone.
It took the company less than nine months to reach a $2 trillion market capitalization after passing the $1 trillion milestone. Nvidia took even less time to go from $2 trillion to $3 trillion, hitting the milestone in 96 days and setting a new record for the short time between the two milestones.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world" target="_blank" rel="noreferrer noopener">briefly became the&nbsp;</a>world&#8217;s most valuable public company earlier this year, passing&nbsp;Apple&nbsp;and&nbsp;Microsoft. With a current market capitalization of $3.308 trillion, Nvidia narrowly trails first-place Apple ($3.466 trillion).
Huang has added $76.6 billion to his wealth in 2024 year-to-date, trailing only Meta Platforms CEO Mark Zuckerberg&#8216;s $80.8 billion gain, who ranks third on the list.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41190198/if-you-invested-1-000-in-nvidia-stock-when-jensen-huang-got-company-logo-tattoo-heres-how-much-">If You Invested $1,000 In Nvidia Stock When Jensen Huang Got Company Logo Tattoo, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Shutterstock

Education

Management

NVDA

Jensen Huang Inches Closer To Top 10 Richest People In The World: Here's How Much More He Needs, How Much Nvidia Stock Must Rise

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $675 to $650.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $650

TOVX

Theriva Biologics Granted Orphan Medicinal Product Designation By European Commission To VCN-01 For Treatment Of Retinoblastoma

ATXS

European Commission Grants Orphan Medicinal Product Designation To Astria Therapeutics' Navenibart For Treatment Of Hereditary Angioedema; Phase 1b/2 Trial Shows 90-96% Reduction In Monthly Attack Rates With Favorable Safety Profile

ALNY

Alnylam Submits Regulatory Application To European Medicines Agency For Vutrisiran To Treat ATTR Amyloidosis With Cardiomyopathy; Submission Based On HELIOS-B Phase 3 Results Showing Significant Reduction In Death And Cardiovascular Events

VP Jennifer Rebeles Contributes To Expert Panel Publishing Best Practices For Rare Sample Testing In Peer-Reviewed Journal

BIAF

bioAffinity's CyPath Lung Cancer Test Backed By New Flow Cytometry Guidelines

Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.

TNXP

Tonix Pharmaceuticals Submits NDA For TNX-102 SL To FDA For Fibromyalgia Treatment; Non-Opioid Analgesic Shows Significant Pain Reduction In Phase 3 Studies And Receives Fast Track Designation

<h3>Gainers</h3>
<ul>
<li>Container Store Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCS#NYSE">TCS</a>) stock moved upwards by 41.5% to $15.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $52.0 million. </li>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) stock rose 10.09% to $0.55. The company's market cap stands at $11.6 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock increased by 9.95% to $7.51. The market value of their outstanding shares is at $18.4 million. </li>
<li>Alta Global Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock moved upwards by 9.89% to $1.57. The market value of their outstanding shares is at $16.4 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares moved upwards by 7.5% to $3.86. The market value of their outstanding shares is at $19.0 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) stock increased by 7.02% to $0.23. The company's market cap stands at $8.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock decreased by 21.0% to $0.18 during Wednesday's pre-market session. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 19.82% to $0.89. The market value of their outstanding shares is at $21.7 million. </li>
<li>TH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THCH#NASDAQ">THCH</a>) shares declined by 12.37% to $0.61. The company's market cap stands at $96.9 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares fell 9.55% to $1.8. The market value of their outstanding shares is at $5.1 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares fell 6.33% to $3.85. The market value of their outstanding shares is at $24.7 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares declined by 6.25% to $0.72. The market value of their outstanding shares is at $26.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBO

CTNT

DBGI

JDZG

THCH

UCAR

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Petros Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the first quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -$1.69. This was below the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $1.39 million.</li><li>This was 4.21% worse than the analyst estimate for revenue of $1.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ptpi-stock-earnings-petros-pharmaceuticals-for-q1-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and keeping the price target at $4.0...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

AEMD

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

PTPI

ROMA

SIFYR

SQNS

VSME

XPON

Contracts

Press Releases

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Comments

Petros Pharma

Noticias

Últimas noticias sobre Petros Pharma (NASDAQ:PTPI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL